Therapeutic Area
Hypertension Clinical Trials — Amavita Research
Cardiovascular trial site for hypertension, conducted at amavita Heart and Vascular Health® in North Miami Beach, FL.
Hypertension affects nearly half of U.S. adults and remains the leading modifiable risk factor for stroke, heart failure, and chronic kidney disease. Many patients remain uncontrolled despite three or more antihypertensive medications, which is the population most modern hypertension trials are designed for. Here is what Amavita Research is currently running in this space.
Active trials at Amavita Research
- Zilebesiran (RNAi) — ALN-AGT01-007
Sponsor: Alnylam Pharmaceuticals (with Duke CRI) · Phase 3
Phase 3 evaluation of zilebesiran, an investigational RNAi therapeutic targeting AGT, in adults with hypertension and elevated cardiovascular risk. Coordinated with Duke Clinical Research Institute.
Principal Investigators in this area
Why Amavita Research for hypertension trials
- High-volume hypertensive patient flow inside amavita Heart and Vascular Health® cardiology clinic — the largest independent cardiovascular practice in South Florida.
- 24-hour ambulatory blood pressure monitoring (ABPM) on-site for protocol-required confirmation of resistant hypertension.
- Renal denervation experience via PI Dr. Pedro Martinez-Clark, MD, FACC.
- Active enrollment on Phase 3 ZENITH zilebesiran (RNAi anti-AGT therapy, Alnylam) coordinated with Duke Clinical Research Institute.
- Bilingual screening (English / Spanish / Haitian Creole / Portuguese) for Miami's multilingual hypertensive population.
Think you might be eligible for a hypertension trial?
Call (786) 703-5941 or use the patient contact form — initial screening is free and takes about 15 minutes.